5/26/18: “We are thrilled to reveal late-breaking data that demonstrates a promising step towards a new therapy for patients suffering from Acute Decompensated Heart Failure,” says Jim Dillon, CEO of RenalGuard Solutions. “RenalGuard-Guided Diuretic Therapy has the potential to establish a new front-line standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss.”

5/25/18: “The expanding adoption of lung cancer screening has given us a real opportunity to catch cancer earlier and save lives, but only if we can help physicians reach the smallest nodules,” said Veran Medical CEO Jason Pesterfield.

5/25/18: Dr. Thompson commented, "I have not been this excited since medical school, the NobleStitch™ EL has changed how I approach cardio-vascular repair. I have never had a product where patients not only call me on a regular basis, but I have patients fly from all over the world requesting to have their procedures using the NobleStitch™ EL. This technology allows me to percutaneously suture the cardiac anatomy and I look forward to the expanded future applications in the heart."

Miracor Medical SA announced today the clinical results from...

5/24/18: "The data from this trial provides further evidence that COBRA PzF NCS is a safe and effective treatment, particularly in complex patients with heart disease," said Luc Maillard, MD, principal investigator for the eCOBRA trial and Director of the Department of Cardiology, Clinique Axium, Aix-en-Provence, France. “Being able to provide an effective therapy that meets the needs of patients who are at higher risk of bleeding is of great clinical value.”

5/24/18: “Hospitals continue to choose Vizient for access to our extensive contract portfolio, sourcing programs, analytics and team of expert advisors to help them meet their clinical and cost reduction goals. We are excited to work with these organizations and help them improve patient outcomes, reduce clinical variation and lower their supply and operating costs,” said Rand Ballard, chief customer officer for Vizient.

5/24/18: In the Onyx 1-Month OCT Study, patients implanted with the Resolute Onyx DES demonstrated an excellent early healing profile with an average of 88 percent of struts covered by neointimal formation (new cell growth over stent struts) and 92.3 percent of the total stented area showing complete strut coverage at one month, which includes the covered areas in between the struts.

5/23/18: Study met all primary and secondary endpoints across multiple measures of breathing and quality of life one year after treatment.

5/23/18: The new algorithm expands Zebra-Med’s footprint into Oncology, with the most affordable Mammo lesion detection package in the market.

5/23/18: "Data from the TARGET AC trial, which included the most complex patient real world population in Europe, demonstrated exceptional performance and safety of the Firehawk® stent," said William Wijns, M.D., PhD, National University of Ireland Galway, Ireland, and principal investigator for the study. "With this European clinical data set, Firehawk® has the potential to positively impact patient care by further reducing the risk of late adverse events and the need for device-mandated prolonged dual antiplatelet therapy, which is often associated with a higher risk of bleeding as well as increased patient treatment cost."

5/23/18:

5/23/18: The retrospective analysis comparing the everlinQ® endoAVF System from TVA Medical, Inc. with surgical arteriovenous fistula (AVF) creation was presented today at ISPOR 2018, the leading global conference for health economics and outcomes research.

5/23/18: The Case Series, authored by Kai-Uwe Lewandrowski, M.D., details a novel endoscopic transforaminal lumbar interbody fusion technique using the VariLift-LX stand-alone expandable interbody fusion device. This surgical technique guide shows that it is feasible to perform a percutaneous endoscopically assisted transforaminal decompression and fusion surgery with the expandable stand-alone VariLift-LX System.

5/23/18: With the acquisition of Bradshaw Medical, In’Tech Medical re-enforces its position as the leading contract manufacturer for Orthopedics, providing end-to-end solutions to its customers worldwide.

5/23/18: "The redesigned website is a reflection of our deep commitment to customer service excellence and technological leadership," said Thomas Chavez, Vice President Global Sales, Cardiology at Baylis Medical.